Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - One more blockbuster drug will be available to U.S. citizens at a fraction of its brand price as India's Dr Reddy's announced the launch of generic versions of GlaxoSmithKline's anti-migraine drug Imitrex (sumatriptan)
You may also be interested in...
Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting
MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone
Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting
MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone
Ranbaxy May Face Third-Party Oversight Of Ganciclovir Manufacturing
Ranbaxy may be subject to third-party supervision of its manufacturing of the antiviral ganciclovir, in return for gaining an exception for the product from U.S. FDA's Import Alert